CL2004000412A1 - Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar. - Google Patents
Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar.Info
- Publication number
- CL2004000412A1 CL2004000412A1 CL200400412A CL2004000412A CL2004000412A1 CL 2004000412 A1 CL2004000412 A1 CL 2004000412A1 CL 200400412 A CL200400412 A CL 200400412A CL 2004000412 A CL2004000412 A CL 2004000412A CL 2004000412 A1 CL2004000412 A1 CL 2004000412A1
- Authority
- CL
- Chile
- Prior art keywords
- treat
- facilitate
- pulmonary hypertension
- hypertension
- treat pulmonary
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 210000003298 dental enamel Anatomy 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000003041 ligament Anatomy 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 210000002435 tendon Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45188903P | 2003-03-04 | 2003-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2004000412A1 true CL2004000412A1 (es) | 2005-02-04 |
Family
ID=32962656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200400412A CL2004000412A1 (es) | 2003-03-04 | 2004-03-02 | Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1601351A1 (de) |
| JP (1) | JP2006519250A (de) |
| KR (1) | KR20050105511A (de) |
| CN (1) | CN1859903A (de) |
| AU (1) | AU2004216898A1 (de) |
| BR (1) | BRPI0408061A (de) |
| CA (1) | CA2518193A1 (de) |
| CL (1) | CL2004000412A1 (de) |
| MX (1) | MXPA05009398A (de) |
| NZ (1) | NZ541828A (de) |
| PL (1) | PL378748A1 (de) |
| TW (1) | TW200424176A (de) |
| WO (1) | WO2004078169A1 (de) |
| ZA (1) | ZA200506532B (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20070270489A1 (en) * | 2003-07-25 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | Remedy for Cartilage-Related Diseases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| DK1848430T3 (da) | 2004-12-31 | 2017-11-06 | Dr Reddys Laboratories Ltd | Nye benzylamin-derivativer som cetp-inhibitors |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
| US7696235B2 (en) | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
| JP5247675B2 (ja) | 2006-03-24 | 2013-07-24 | チルドレンズ メディカル センター コーポレーション | 造血性幹細胞の増殖を調節する方法 |
| NZ573964A (en) | 2006-07-28 | 2010-11-26 | Pfizer Prod Inc | isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma |
| JP5426389B2 (ja) * | 2006-10-20 | 2014-02-26 | チルドレンズ メディカル センター コーポレーション | 組織の再生を亢進するための方法 |
| CN101828111B (zh) * | 2007-08-21 | 2014-07-23 | 塞诺米克斯公司 | 人t2r苦味受体及其用途 |
| CN103965099A (zh) * | 2008-03-12 | 2014-08-06 | 宇部兴产株式会社 | 吡啶基氨基乙酸化合物 |
| WO2010096264A2 (en) | 2009-02-03 | 2010-08-26 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| US9051548B2 (en) | 2009-02-03 | 2015-06-09 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| PL2415763T3 (pl) | 2009-03-30 | 2016-05-31 | Ube Industries | Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| WO2011030873A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | ベンジル化合物 |
| CN102548985A (zh) * | 2009-09-11 | 2012-07-04 | 宇部兴产株式会社 | 取代羰基化合物 |
| WO2011030872A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | スルホンアミド化合物 |
| WO2011030865A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | 置換ベンジル化合物 |
| JP2011057633A (ja) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
| CN102498101A (zh) * | 2009-09-11 | 2012-06-13 | 宇部兴产株式会社 | 苯胺化合物 |
| WO2011030871A1 (ja) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | Ｎ－置換ヘテロアリール化合物 |
| WO2011078303A1 (ja) | 2009-12-25 | 2011-06-30 | 宇部興産株式会社 | アミノピリジン化合物 |
| KR101774223B1 (ko) | 2011-08-18 | 2017-09-12 | 닥터 레디스 레보러터리즈 리미티드 | 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물 |
| HK1197238A1 (en) | 2011-09-27 | 2015-01-09 | 雷迪博士实验室有限公司 | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
| CA2857640C (en) | 2011-12-02 | 2021-11-16 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| ES2682255T3 (es) | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
| EP2804605A4 (de) * | 2012-01-20 | 2015-07-08 | Acucela Inc | Substituierte heterocyclische verbindungen zur behandlung von krankheiten |
| US20140142092A1 (en) * | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Compounds and methods for skin repair |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| JPWO2014157672A1 (ja) | 2013-03-28 | 2017-02-16 | 宇部興産株式会社 | 置換ビアリール化合物 |
| EP4474384A1 (de) | 2014-05-13 | 2024-12-11 | Novartis AG | Verbindungen und zusammensetzungen zur induktion von chondrogenese |
| CN106397149B (zh) * | 2016-08-26 | 2019-05-21 | 大连奇凯医药科技有限公司 | 五氟苯甲醛的制备方法 |
| CN115636761B (zh) * | 2021-07-20 | 2024-07-05 | 中国石油天然气股份有限公司 | 一种油溶性表面活性剂、驱油剂及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2113787A1 (en) * | 1993-01-29 | 1994-07-30 | Nobuyuki Hamanaka | Carbocyclic sulfonamides |
| DK0951282T3 (da) * | 1996-12-20 | 2008-07-14 | Pfizer | Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister |
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US6376533B1 (en) * | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
-
2004
- 2004-02-23 AU AU2004216898A patent/AU2004216898A1/en not_active Abandoned
- 2004-02-23 JP JP2006506276A patent/JP2006519250A/ja not_active Withdrawn
- 2004-02-23 MX MXPA05009398A patent/MXPA05009398A/es unknown
- 2004-02-23 WO PCT/IB2004/000553 patent/WO2004078169A1/en not_active Ceased
- 2004-02-23 EP EP04713611A patent/EP1601351A1/de not_active Withdrawn
- 2004-02-23 CN CNA2004800085767A patent/CN1859903A/zh active Pending
- 2004-02-23 KR KR1020057016414A patent/KR20050105511A/ko not_active Ceased
- 2004-02-23 BR BRPI0408061-0A patent/BRPI0408061A/pt not_active IP Right Cessation
- 2004-02-23 PL PL378748A patent/PL378748A1/pl not_active Application Discontinuation
- 2004-02-23 CA CA002518193A patent/CA2518193A1/en not_active Abandoned
- 2004-02-23 NZ NZ541828A patent/NZ541828A/en unknown
- 2004-03-01 TW TW093105312A patent/TW200424176A/zh unknown
- 2004-03-02 CL CL200400412A patent/CL2004000412A1/es unknown
-
2005
- 2005-08-16 ZA ZA200506532A patent/ZA200506532B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006519250A (ja) | 2006-08-24 |
| CN1859903A (zh) | 2006-11-08 |
| TW200424176A (en) | 2004-11-16 |
| AU2004216898A1 (en) | 2004-09-16 |
| BRPI0408061A (pt) | 2006-02-14 |
| KR20050105511A (ko) | 2005-11-04 |
| WO2004078169A8 (en) | 2005-04-21 |
| ZA200506532B (en) | 2007-03-28 |
| NZ541828A (en) | 2008-06-30 |
| MXPA05009398A (es) | 2005-12-05 |
| CA2518193A1 (en) | 2004-09-16 |
| EP1601351A1 (de) | 2005-12-07 |
| WO2004078169A1 (en) | 2004-09-16 |
| PL378748A1 (pl) | 2006-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2004000412A1 (es) | Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar. | |
| ECSP056037A (es) | Agonista del receptor ep4, composiciones y procedimientos del mismo | |
| EA200702346A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| ECSP045203A (es) | Cicloalcanindoles con sustitución con flúor y su uso como antagonistas del receptor prostaglandina d2 | |
| SV2005002148A (es) | "compuestos moduladores de la actividad c-kit y usos de los mismos" | |
| AR035275A1 (es) | Tieniloxipirimidinas n-heterociclil-sustituidas | |
| ECSP066756A (es) | Anticuerpo monoclonal específico m-csf y los usos del mismo | |
| CY1105080T1 (el) | Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| CO2021006482A2 (es) | Ureas cíclicas | |
| CY1108430T1 (el) | Χρηση ανταγωνιστων διαυλου νευρωνικου νατριου μαζι με αμιτραζ για τον ελεγχο εκτοπαρασιτων σε ομοιοθερμικα ζωα | |
| CR7928A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension | |
| ATE485269T1 (de) | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden | |
| CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
| EA200301142A1 (ru) | Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| WO2003047513A3 (en) | Method for treating ocular hypertension | |
| ATE415817T1 (de) | Agrochemische formulierungen | |
| EP1732484A4 (de) | Ophthalmisches implantat zur behandlung von glaukom | |
| CL2003002769A1 (es) | Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid | |
| GT200500309A (es) | Derivados de sulfonilbencilimidazol | |
| CY1105877T1 (el) | Οφθαλμικες συνθεσεις πepιεχουσες συνepγιστικο συνδυασμο τριων πολυμepων | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| UY28098A1 (es) | Derivados de anilinopirazol útiles en el tratamiento de la diabetes | |
| DOP2003000747A (es) | Composiciones oftalmicas para el tratamiento de la hipertension ocular | |
| MXPA04004236A (es) | Metodo para la formacion de cristales ibuprofeno. |